Zusammenfassung
Hintergrund: Non-Compliance (oder Non-Adherence) mit antipsychotischer Pharmakotherapie kommt häufig vor und stellt ein Risiko für psychotische Rückfälle dar, das wissenschaftlich sehr gut belegt ist. Compliance ist von großer Bedeutung für den Verlauf und die Behandlung schizophrener Psychosen. Ein Schwerpunkt der Forschung gilt der Compliance mit antipsychotischer Pharmakotherapie. Methode: Die Arbeit gibt eine Übersicht der Ergebnisse aus Metaanalysen. Literaturreviews der internationalen psychiatrischen Literatur seit 1990 zu Effekten von Interventionen, die zum Ziel haben, die Medikamentencompliance bei Schizophreniekranken zu erhöhen, werden zusammenfassend referiert. Ergebnisse: Es fanden sich acht aktuelle Übersichtsarbeiten zur Effektivität compliancesteigernder Maßnahmen bei Schizophreniepatienten. Interventionen zur Besserung non-complianten Verhaltens zeigten bislang wenig (Psychoedukation) bis mittelstarke (kognitiv-behaviorale und multimodale Interventionen) Effekte. Weitere relevante Befunde werden zusammenfassend berichtet und kritisch diskutiert.
Abstract
Background: Non-compliance (or non-adherence) with antipsychotic pharmacotherapy occurs frequently. In addition, there is overwhelming evidence that it constitutes a major risk factor for psychotic relapse. Compliance substantially affects course and treatment of schizophrenia. During the last decades, a large body of research on compliance with antipsychotic medication has been accumulated. Method: The authors provide an overview of meta-analyses. Reviews published since 1990 on effects of interventions aiming at increasing compliance with medication in people suffering from schizophrenia are summarized. Results: We found eight reviews which reported empirical findings on the efficacy and effectiveness of interventions with the goal of improving compliance. Interventions have shown limited (psychoeducation) to moderate (cognitive-behavioral and combined interventions) effects. Other relevant findings are summarized and discussed.
Literatur
1 Thornley B, Rathbone J, Adams C E, Awad G. Chlorpromazine versus placebo for schizophrenia (Cochrane review). Chichester, U. K.; John Wiley u. Sons 2003
2 Hunter R H, Joy C B, Kennedy E, Gilbody S M, Song F. Risperidone versus typical antipsychotic medication for schizophrenia (Cochrane review). Chichester, U. K.; John Wiley u. Sons 2003
3 Wahlbeck K, Cheine M, Essali M A. Clozapine versus typical neuroleptic medication for schizophrenia (Cochrane review). Chichester, U. K.; John Wiley u. Sons 2003
4
Hornung W P, Franzen U, Lemke R, Wiesemann C, Buchkremer G.
Kann Psychoedukation bei chronisch schizophrenen Patienten kurzfristig medikationsbezogene Einstellungen und Verhaltensweisen beeinflussen?.
Psychiat Prax.
1993;
20
152-154
5 Haynes R B. Introduction. In: Haynes RB, Taylor DW, Sacket DL (eds) Compliance in Health Care. Baltimore; John Hopkins Press 1979: 1-10
6
Stimson G V.
Obeying doctors' orders: A view from the other side.
Social Science and Medicine.
1974;
8
97-194
7
Holm S.
What is wrong with compliance?.
Journal of Medical Ethics.
1993;
19
108-110
8
Bebbington P.
The content and context of compliance.
International Clinical Psychopharmacology.
1995;
9 (5)
41-50
9
Lingam R, Scott J.
Treatment non-adherence in affective disorders.
Acta Psychiatrica Scandinavia.
2002;
105
164-172
10
Dodds F, Rebair-Brown A, Parsons S.
A systematic review of randomized controlled trials that attempt to identify interventions that improve patient compliance with prescribed antipsychotic medication.
Clinical Effectiveness in Nursing.
2000;
4
47-53
11
Gray R, Wykes T, Gournay K.
From compliance to concordance: A review of the literature on interventions to enhance compliance with antipsychotic medication.
Journal of Psychiatric and Mental Health Nursing.
2002;
9 (3)
277-284
12
Lacro J P, Dunn L B, Dolder C R, Leckband S G, Jeste D V.
Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: A comprehensive review of recent literature.
J Clin Psychiatry.
2002;
63 (10)
892-909
13
Fenton W S, Blyler C R, Hummer M.
Determinants of medication compliance in schizophrenia: Empirical and clinical findings.
Schizophrenia Bulletin.
1997;
23 (4)
637-651
14
Haynes R B, McKibbon K A, Kanani R.
Systematic review of randomized trials of interventions to assist patients to follow prescriptions for medications.
The Lancet.
1996;
348
383-386
15
Oehl M, Hummer M, Fleischhacker W W.
Compliance with antipsychotic treatment.
Acta Psychiatrica Scandinavia.
2000;
102
83-86
16
Helgason L.
Twenty years' follow-up of first psychiatric presentation for schizophrenia: what could have been prevented?.
Acta Psychiatrica Scandinavia.
1990;
81
231-235
17
Green J H.
Frequent rehospitalization and noncompliance with treatment.
Hosp Community Psychiatry.
1988;
39 (9)
963-966
18
Haywood T W, Kravitz H M, Grossman L S, Cavanaugh jr J L, Davis J M, Lewis D A.
Predicting the „revolving door” phenomenon among patients with schizophrenic, schizoaffective, and affective disorders.
Am J Psychiatry.
1995;
152 (6)
856-861
19
Curson D A, Barnes T R, Bamber R W, Platt S D, Hirsch S R, Duffy J C.
Long-term depot maintenance of chronic schizophrenic out-patients: The seven year follow-up of the Medical Research Council fluphenazine/placebo trial. II. The incidence of compliance problems, side-effects, neurotic symptoms and depression.
British Journal of Psychiatry.
1985;
146
469-474
20
Coldham E L, Addington J, Addington D.
Medication adherence of individuals with a first episode of psychosis.
Acta Psychiatrica Scandinavia.
2002;
106 (4)
286-290
21 Kemp R, Hayward P, David A. Compliance therapy manual. London; The Bethlem and Maudsley NHS Trust 1997
22
Zygmunt A, Olfson M, Boyer C A, Mechanic D.
Interventions to improve medication adherence in schizophrenia.
American Journal of Psychiatry.
2002;
59
1653-1664
23
Kampman O, Lethinen K.
Compliance in psychosis.
Acta Psychiatrica Scandinavia.
1999;
100
167-175
24
Dolder C, Lacro J, Leckband S, Jeste D.
Interventions to improve antipsychotic medication adherence: Review of recent literature.
Journal of Clinical Pharmacology.
2003;
23 (4)
389-399
25
Nose M, Barbui C, Gray R, Tansella M.
Clinical interventions for treatment non-adherence in psychosis: Meta-analysis.
British Journal of Psychiatry.
2003;
183
197-206
26
Kemp R, Kirov G, Everitt B, Hayward P, David A.
Randomised controlled trial of compliance therapy: 18-month follow-up.
British Journal of Psychiatry.
1998;
172
413-419
27
Kemp R, Hayward P, Applewhaite G, Everitt B, David A.
Compliance therapy in psychotic patients: Randomised controlled trial.
BMJ.
1996;
312
345-349
28 Becker M H. Understanding patient compliance: The contribution of attitudes and other psychosocial factors. In: Cohen SJ (ed) New Directions in patient compliance. Lexington, MA; D. C. Heath and Co 1979: 1-31
29
Awad A G, Hogan T P, Voruganti L N, Heslegrave R J.
Patients' subjective experiences on antipsychotic medications: Implications for outcome and quality of life.
International Clinical Psychopharmacology.
1995;
10, Suppl 3
123-132
30
Löffler W, Kilian R, Toumi M, Angermeyer M.
Schizophrenic patients' subjective reasons for compliance and noncompliance with neuroleptic treatment.
Pharmacopsychiatry.
2003;
36 (3)
105-112
31
Geddes J.
Generating evidence to inform policy and practice: The example of the second generation „atypical” antipsychotics.
Schizophrenia Bulletin.
2003;
29 (1)
105-114
32
McDonald H, Garg A, Haynes R.
Interventions to enhance patient adherence to medication prescriptions.
Journal of the American Medical Association.
2002;
288 (22)
2867-2879
33
O'Donnell C, Donohoe G, Sharkey L, Owens N, Migone M, Harries R. et al .
Compliance therapy: A randomised controlled trial in schizophrenia.
BMJ.
2003;
327 (7419)
834-840
34
Roter D L, Hall J A, Merisca R, Nordstrom B, Cretin D, Svarstad B.
Effectiveness of interventions to improve patient compliance: A meta-analysis.
Med Care.
1998;
36
1138-1161
1 Ausschließlich der besseren Lesbarkeit wegen wird die männliche Form verwendet. Natürlich sind mit Patienten auch Patientinnen, mit Ärzten auch Ärztinnen usw. gemeint.
Dr. Bernd Puschner
Abteilung Psychiatrie II der Universität Ulm · Bezirkskrankenhaus Günzburg
Ludwig-Heilmeyer-Straße 2
89312 Günzburg
Email: bernd.puschner@bkh-guenzburg.de